Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Published on July 8, 2025
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
Continue reading on website
Other news

Five insights from the GOC

July 8, 2025
Public perceptions research and an evaluation of the 2022–2024 CPD cycle were presented at the latest meeting of the optical regulator

AOA 2025: Optometry and visual impairment in Latin America

July 8, 2025
Carlos Chacon, MSc OD, FIACLE, cited economic and geographic barriers and non-standardized education as the major barriers keeping patients from adequate eye care in Latin America.